FindTrial
Sign In

Exploring the value of molecular imaging technology in fibrosing interstitial lung disease for early diagnosis, clinical relevance and prognosis prediction

Exploring the value of molecular imaging technology in fibrosing interstitial lung disease for early diagnosis, clinical relevance and prognosis prediction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081292
Enrollment
Unknown
Registered
2024-02-28
Start date
2024-03-11
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibrotic interstitial lung disease

Interventions

Observation Group:NA

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Eligible patients were adults (=18 years of age) with a physician-diagnosed fibrotic interstitial lung disease.

Exclusion criteria

Exclusion criteria: Patients who could not be followed up according to the study protocol were excluded. Women who were pregnant were excluded.

Design outcomes

Primary

MeasureTime frame
68Ga-FAPI-PET/CT imaging data;—

Secondary

MeasureTime frame
Forced vital capacity;—

Countries

China

Contacts

Public ContactHui Huang

Peking Union Medical College Hospital

pumchhh@126.com+86 135 2112 8207

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026